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ABBREVIATIONS 
AD atopic dermatitis 
ANA antinuclear antibodies 
anti-DGP antibodies against deamidated form of gliadin peptides 
anti-TG2 antibodies against tissue transglutaminase (TG2) 
AU arbitrary units 
CD coeliac disease 
CI confidential interval 
DH dermatitis herpetiformis 
dsDNA double stranded DNA 
ELISA enzyme-linked immunosorbent assay 
EmA antibodies against endomysium 
ESPGHAN European Society for Paediatric Gastroenterology, Hepatology 
and Nutrition 
HLA human leukocyte antigen 
IFN-γ interferon-γ 
IgA immunoglobulin A 
IgA-anti-DGP IgA type antibodies to DGP 
IgA-anti-TG1 IgA type antibodies to TG1 
IgA-anti-TG2 IgA type antibodies to TG2 
IgA-anti-TG3 IgA type antibodies to TG3 
IgE immunoglobulin E 
IgG immunoglobulin G 
IgG-anti-DGP IgG type anti-DGP 
IgG-anti-TG2 IgG type anti-TG2 
IgM  immunoglobulin M 
IL interleukin 
IL-3 interleukin 3 
IL-4 interleukin 4 
IL-5 interleukin 5 
IL-10 interleukin 10 
IL-12 interleukin 12 
IL-13 interleukin 13 
IL-18 interleukin 18 
IR incidence rate 
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OR odds ratio 
PBS phosphate-buffered saline 
Tc cytotoxic T-cell 
TG1 transglutaminase 1, keratinocyte transglutaminase  
TG2 transglutaminase 2, tissue transglutaminase 
TG3 transglutaminase 3, epidermal transglutaminase 
Th helper T-cell 
Th1 type 1 helper T-cell 
Th2 type 2 helper T-cell 
TNF- tumour necrosis factor  







Coeliac disease (CD) and atopic dermatitis (AD) are two of the most common 
immune mediated chronic diseases in childhood. 
CD is an autoimmune disorder of the small intestine in which the ingestion 
of gluten and related cereals leads to chronic inflammation and damage of the 
small intestinal mucosa in genetically susceptible individuals (Fasano et al 
2012; Kneepkens et al 2012). Traditionally CD has been considered a rare 
disease of childhood, manifesting during the first years of life as mainly 
gastrointestinal symptoms. On the basis of prevalence figures (0.1% or less) 
based mainly on clinical diagnosis, CD was previously regarded as rare in 
different populations and countries, including Estonia (Uibo 1994a; Mäki et al 
2003; Myleus et al 2009; Mustalahti et al 2010). In recent years it has become 
evident, that CD occurs more frequently worldwide than previously thought and 
the clinical spectrum of the disease is highly variable. Nowadays, most of 
patients tend to present with atypical clinical symptoms and an increasing 
number of patients are diagnosed based on screening the risk groups (Kang et al 
2013; Mustalahti et al 2010). CD has been associated with a list of diseases and 
conditions, type 1 diabetes being the most common comorbidity (Holmes 2001; 
Barker et al 2008; Volta et al 2011; Elli et al 2012). In case of comorbidities, 
CD often presents with atypical or asymptomatic clinical picture, leading to late 
or even missed diagnosis. 
AD is a multifactorial chronic inflammatory skin disease, characterised by 
intense pruritus and relapsing eczema (Bieber 2008). Previously considered a 
disease purely mediated by type 2 helper T-cell (Th2) type responses, but the 
role of type 1 helper T-cell (Th1) responses and autoimmune reactions has since 
been revealed, especially in the chronic phase of the disease (Simpson et al 
2002; Bieber 2008; Valenta et al 2009; Tang et al 2012). It has been proposed, 
that AD is the cutaneous manifestation of a systemic allergic disease, therefore 
being associated with other allergic diseases (Spergel et al 2003). As AD is 
often linked to food allergy, it suggests a potential causative role for changes at 
the small intestinal mucosal level in the pathogenesis of AD. 
Both CD and AD have complex etiologies with genetic predisposition, 
environmental factors and immunoregulatory mechanisms playing an important 
role in their pathogenesis (Kupfer et al 2012; Meresse et al 2012; Leung 2013). 
So far, only a few studies have investigated the coexistence of CD and atopic 
disorders, especially AD. Although it has been suggested that these two diseases 
may coexist, it is still not known, whether the coexistence of CD and AD could 
be coincidental or whether there is a real association.  
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2. BACKGROUND TO THE STUDY 
2.1. Coeliac disease (CD) 
CD develops by the ingestion of wheat gluten and related prolamines in rye, 
barley, and possibly oats leading to chronic inflammation and autoimmune 
damage of the small intestinal mucosa in genetically susceptible individuals. 
During the last decades, it has become evident that CD occurs more 
frequently worldwide than previously thought, showing a prevalence of up to 
3% in Western populations (Mäki et al 2003; Myleus et al 2009; Kang et al 
2013; Lundin et al 2014). There has been a nearly two times increase in the 
prevalence of CD over two decades in Finland and more than four times 
increase in the United States over the past 50 years (Lohi et al 2007; Rubio-
Tapia et al 2009).  
For a long time, Estonia has been a country with a low prevalence of CD – 
screening studies carried out in 1990 and 1998 on the general population (in 
total 1939 children and adults) showed absence of CD cases (Uibo et al 1993; 
Metsküla et al 1998). In 1990–1994 an active search and screening for CD with 
immunoglobulin A (IgA) type antigliadin antibodies was carried out, leading to 
an increase in the incidence of CD (0.37 cases per 1000 live births), but the 
prevalence still remained low compared to other countries (Uibo 1994a; Uibo 
1994b; Uibo et al 1996). 
Genetic predisposition plays an important role in the pathogenesis of CD. 
Approximately 95% of patients carry the human leukocyte antigen (HLA) 
DR3DQ2 (DQA1*05:01 and DQB1*02:01 alleles), the remainder having the 
HLA DR4DQ8 haplotype (DQA1*03 and DQB1*03:02 alleles) (Fasano et al 
2012). The frequency of relevant HLA haplotypes in the Estonian background 
population are comparable to the ones of neighbouring countries, including 
Finland – HLA DR3DQ2 haplotype has been found in 22.3% of Estonian and in 
20.2% of Finnish population and DQB1*03:02 allele has been found in 17.8% 
and 19.3% respectively (Nejentsev et al 1998). As up to 40% of general 
population has the HLA DQ2 haplotype, other genes must be involved in the 
pathogenesis on CD (Kagnoff 2005; Heel et al 2006). In addition to HLA that 
account about 40% of CD predisposition, non-HLA genes have been found to 
determine about 14% of genetics of CD (Lundin et al 2014). 
It has been established that both innate and adaptive immune responses have 
a role to play in the pathogenesis of CD (Heel et al 2006; Meresse et al 2012; 
Qiao et al 2012). The cascade of pathophysiological processes starts with 
impairment of the barrier in small intestinal mucosa and presentation of the 
toxic peptides to HLA DQ2 and/or DQ8 molecules expressed on antigen 
presenting cells. By the activation of antigen-specific helper T-cells (Th) several 
proinflammatory cytokines are released, for example interferon- (IFN-), 
interleukins (IL) 4 (IL-4) and 10 (IL-10), tumour necrosis factor  (TNF-). 
This is followed by proliferation of autoreactive B-cells and production of 
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immunoglobulin A, G or M (IgA, IgG, IgM) type antibodies against a 
deamidated form of gliadin peptides (anti-DGP), endomysium (EmA) and tissue 
transglutaminase (anti-TG2) by plasma cells. Tissue transglutaminase (TG2) 
has been recognised as the target autoantigen for CD, as it has a role in 
deamidating the gliadin peptides (Heel et al 2006; Klöck et al 2012). The most 
characteristic finding of the multiple immune reactions in the pathogenesis is 
the presence of IgA-type antibodies to TG2 (IgA-anti-TG2). The activation of 
cytotoxic T-cells (Tc) and production of new cytokines leads to destruction of 
mucosal cells, crypt hyperplasia and villous atrophy. As a result of villous 
atrophy and crypt hyperplasia the classical symptom of CD is the malabsorption 
syndrome (Lundin et al 2014).  
CD was first described by Samuel Gee in 1888 as a disease affecting both 
children and adults and presenting with periodic diarrhoea, weight loss and 
abdominal distension (Gee 1888). Today it is known that the clinical spectrum 
of CD is highly variable. Patients with classical clinical picture present with 
diarrhoea and failure to thrive and/or weight loss. Still most cases may be left 
undiagnosed as the majority of patients present with atypical symptoms –
different gastrointestinal symptoms without failure to thrive or weight loss, 
extraintestinal symptoms or are asymptomatic (indentified as a consequence of 
screening) (Catassi et al 2002; Tikkakoski et al 2007; Giongo et al 2011; Husby 
et al 2012). Based on new diagnostic guideline for CD, it has been proposed to 
group the clinical symptoms of CD into gastrointestinal and extraintestinal 
symptoms and signs (Husby et al 2012). CD is defined as a silent form in case 
of positivity in CD-specific antibodies, HLA and small intestinal biopsy finding 
compatible with CD, despite insufficient symptoms and signs for clinical 
suspicion of CD. Latent CD is defined by the presence of HLA in the absence 
of enteropathy in a patient earlier diagnosed with CD. Potential CD can be 
defined by the presence of CD-specific antibodies and HLA in the absence of 
histological changes at the mucosal level (Husby et al 2012). 
CD can be suspected based on clinical picture and serological testing results 
– anti-TG2, EmA and anti-DGP. However, definitive diagnosis requires 
documenting the histopathological changes in the small intestinal biopsy (Marsh 
1992; Husby et al 2012). The only available effective treatment for CD patients 
is lifelong and strict gluten-free diet (Walker-Smith et al 1990; Husby et al 
2012). As a rule an adequate diet results in complete resolution of serological 
and histological changes and complete disappearance of symptoms. Early 
identification and adequate treatment enables prevention of several important 
complications associated with CD, above all growth failure, disturbances of 
reproductive function, dental structural defects, iron-deficiency anaemia, 
osteoporosis and malignant tumours (Collin et al 1994; Haapalahti et al 2005; 




2.2. Atopic dermatitis (AD) 
AD is a multifactorial chronic inflammatory skin disease, characterised by dry 
skin, intense pruritus, relapsing eczema with typical distribution of the skin 
lesions. Although AD does not have pathognomonic skin lesions or laboratory 
features, erythematous papules associated with excoriations, vesiculations and 
serous exudate are prevalent in acute AD. Subacute and chronic AD can be 
characterised by erythematous, excoriated, scaling papules and lichenification 
(Adkinson et al 2009). AD usually presents during infancy and childhood, but it 
can persist or start in adulthood as well (Bieber 2008). During infancy children 
have primarily eczema on the face and extensor surfaces of the extremities, but 
in older patients the flexural folds are predominantly involved (Adkinson et al 
2009). The lifetime prevalence of AD is 10–20% in Estonian children (Voor et 
al 2005). 
AD has a complex etiology with genetic predisposition, congenital skin 
barrier defects, environmental factors, microbial colonisation and immuno-
regulatory mechanisms playing an important role (Silverberg et al 2012; 
Eyerich et al 2013; Leung 2013). A combination of genetic and acquired factors 
contributes to reduced epidermal differentiation and down-regulation of 
epidermal barrier function (Cork et al 2009; Kubo et al 2012; Wolf et al 2012). 
Following breakdown of the epidermal barrier both innate and adaptive immune 
mechanisms play a role. In the acute phase of the disease, after the allergen 
uptake and processing by Langerhans’ cells, they are presented to naive Th 
cells, leading to induction of Th2 differentiation and cytokine release (IL-3, 
IL-4, IL-5, IL-13), allergen-specific immunoglobulin E (IgE) production by 
plasma cells and activation of eosinophils. The adaptive immune response 
contributes also to reduced epidermal differentiation and to reduced anti-
microbial peptide expression (Cork et al 2009; Kubo et al 2012; Leung 2013). 
AD was previously considered a purely Th2 and IgE mediated inflammatory 
disease, but recent investigations have revealed an important role of Th1 type 
responses in the pathogenesis of the disease (Bieber 2008; Eyerich et al 2013). 
Mechanical trauma, microbial toxins, and secretion of proinflammatory 
cytokines (IL-12, IL-18) by inflammatory dendritic epidermal cells and 
eosinophils contribute to the switch from Th2 to Th1 and thereby lead to the 
chronic phase of disease (Bieber 2008; Leung 20s13).  
It has been suggested that AD is the cutaneous manifestation of a systemic 
allergic disease that also gives rise to asthma, food allergy and allergic rhinitis 
(Spergel et al 2003; Dharmage et al 2014). Patients with AD and food allergy 
have been reported to have increased intestinal permeability, indicating a 
possible causative role for intestinal permeability changes in AD pathogenesis 
(Verkasalo et al 1983; Husby 1988; Räsänen et al 1994; Leung et al 2003). 
Increased permeability may be the primary abnormality of the gut or reflect 
intestinal mucosal damage caused by local immunological reactions to antigens 
(Pike et al 1986). Recently, Järvinen et al investigated a large cohort of children 
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with food allergy on a specific elimination diet and suggested increased 
permeability to be the intrinsic trait in a subset of patients (Järvinen et al 2013). 
Although in CD patients, the histological changes in small intestinal mucosa 
improve within 9–12 months after starting gluten-free diet (Selby et al 1999), 
repeated evaluation of food allergy patients showed stable intestinal 
permeability (Järvinen et al 2013). Therefore increased intestinal permeability 
could play important role in pathogenesis of food allergy as well as in AD.  
The clinical phenotype of AD has been classified into extrinsic and intrinsic 
types, the latter comprising 10–45% of AD patients (Novak et al 2003; Tokura 
2010). The intrinsic type reflects the non-allergic form of AD with normal IgE 
levels and absence of any detectable allergen sensitisation. Almost 2/3 of 
children that present with the clinical phenotype of AD have no identifiable 
allergen-specific sensitisation. On the other hand, in patients with extrinsic or 
allergic type of AD the serum IgE levels are increased together with 
sensitisation toward environmental allergens (Schmid-Grendelmeier et al 2001). 
Based on earlier studies sensitisation to food allergens frequently occurs in 
children with AD (10–50%), but food as a trigger of AD has long been a subject 
of debate (Ellman et al 2002; Fuiano et al 2012; Moghtaderi et al 2012). 
 
 
2.3. Coexistence of CD and AD 
During the last decades, the pathomechanism of AD has consistently been under 
investigation and the possible role for autoimmune mechanisms has been 
discussed (Valenta et al 1999; Rabin et al 2008; Tang et al 2012; Leung 2013). 
Various immune-mediated and non-immune mediated diseases may be 
associated with AD, including autoimmune diseases like CD (Simpson et al 
2002; Rabin et al 2008; Silverberg et al 2012).  
CD has been associated with an expanding list of diseases and conditions, 
autoimmune and non-autoimmune, and in most of these cases CD remains 
undiagnosed because of atypical or asymptomatic presentation (Catassi et al 
2002; Green et al 2007). Some of the concomitant conditions are the mani-
festations of untreated malabsorption. However, in most cases, it is still a matter 
of discussion whether there is a pathogenetic association. Type 1 diabetes, 
autoimmune liver disease, autoimmune thyroid disease, Addison’s disease, 
some chromosomal aberration disorders (Turner, Down and Williams 
syndromes), connective tissue disorders, IgA deficiency, IgA nephropathy and 
atopy are the most often reported concomitant disorders (Bottaro et al 1999; 




Table 1. Overview of relevant studies on AD/atopy and CD published in PUBMED 
until January 2014*. 
Reference Country Study subjects, n No of cases found, (%) 
Atopy in CD patients    
   Bottaro et al, 1999 Italy children and adults with CD, 
n=1026 
8 (0.8%) with atopy 
   de Freitas et al, 2002 Brazil adults with CD, n=48 3 (6%) with atopy 
   Kotze, 2009  Brazil children and adults with CD, 
n=157 
35 (22.3%) with atopy 
AD in CD patients    
   Cooper et al, 1978 UK adults with CD, n=314 17 (5.4%) with AD 
   Verkasalo et al, 1983 Finland children with CD, n=42 19 (45.2%) with AD 
   Williams, 1987  UK adults with CD, n=76 5 (7%) with AD 
   Greco et al, 1990  Italy children with CD, n=82 11 (13%) with AD 
   Ciacci et al, 2004  Italy adults with CD, n=1044 40 (3.8%) with AD 
   Elli et al, 2012 Italy children and adults with CD, 
n=1015 
15 (1.5%) with AD 
CD in atopy patients    
   Zauli et al, 2000  Italy children and adults with atopy, 
n=401  
4 (1.0%) with CD 
CD in AD patients    
   Gallo et al, 1992  Italy patients with AD, n=13 3 (23%) with CD 
   Uibo et al, 1996  Estonia children with AD, n=105 1 (0.9%) with CD 
* Based on an electronic search conducted in PUBMED (US National Library of Medicine) for 
all publications reporting on atopic dermatitis and coeliac disease. Using keywords “atopic 
dermatitis”, “atopic eczema”, “atopy”, “celiac disease”, “coeliac disease” and “gluten sensi-
tive enteropathy” the search resulted in 73 publications. Selection was made based on screening 
titles and abstracts. 
 
Only a few earlier reports refer to the possibility that CD and AD could coexist 
frequently (Table 1)(Cooper et al 1978; Verkasalo et al 1983; Williams 1987; 
Greco et al 1990; Gallo et al 1992; Uibo et al 1996; Bottaro et al 1999; Zauli et 
al 2000; Ciacci et al 2004; Kotze 2009; Elli et al 2012). In several reports 
patients with CD were observed more atopic than the general population. 
Verkasalo et al showed the 45% prevalence of AD among Finnish school-
children with CD, compared to 25% prevalence of AD in the general population 
(Verkasalo et al 1983). Italian authors have shown, in a large group of CD 
patients that atopy is the most frequently associated disease after type 1 diabetes 
and that patients with CD have a 3-fold risk to have AD compared to the 
general population (Zauli et al 2000; Ciacci et al 2004).  
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On the other hand, CD has also been found more frequently in atopic 
patients than in the general population. Zauli et al have found 1% prevalence of 
CD in patients with different atopic diseases compared to 0.2% prevalence in 
the general population (Zauli et al 2000). In an earlier study, Uibo et al has 
found CD in 0.9% of Estonian children with AD, using antigliadin antibodies 
for screening (Uibo et al 1996). It is still not clear, whether the coexistence of 
CD and AD could be coincidental or whether there is a real association. 
 
 
2.4. Antinuclear antibodies in AD 
During the last decades, the possible role of autoimmunity in AD pathogenesis 
has been discussed. AD has a pattern of relapsing-remitting disease, similar to 
other chronic autoimmune diseases (Tokura 2010; Tang et al 2012). In general, 
autoimmune reactions have been reported in patients with AD more frequently 
than in the general population (Ohkouchi et al 1999; Higashi et al 2009; Tang et 
al 2012). Moreover, it has been shown that in chronic and severe forms of AD, 
high percentage of patients display IgE autoreactivity to a broad spectrum of 
human proteins, which are expressed in a variety of cell and tissue types 
(Valenta et al 2009). During exacerbation of skin manifestations, IgE auto-
antibody levels have been shown to be increased (Mittermann et al 2004).  
Antinuclear antibodies (ANA) are the most commonly detected auto-
antibodies in various patient groups (Breda et al 2010). Several laboratories 
have reported the presence of ANA in 19–41% of patients with AD, which is 
higher than in the general population (Ohkouchi et al 1999; Higashi et al 2009; 
Tang et al 2012). Some studies have shown association with a presence of ANA 
in higher titers and especially in patients with severe facial lesions (Valenta et al 
1999; Muro 2001; Higashi et al 2009). However, more recent studies have not 
confirmed the relationship between ANA positivity and facial lesions (Tang et 
al 2012). 
The role of autoimmune reactions in the development of AD is still unclear. 
Although, higher prevalence of autoimmune reactions might suggest a subtype 
of AD.  
 
 
2.5. Transglutaminases as antibody targets 
Transglutaminases are a family of calcium-dependent enzymes that have an 
important role in various biological processes, including cell structure 
organisation and apoptosis. As mentioned earlier, TG2 has been recognised as 
the target autoantigen for CD (Dieterich et al 1997), and IgA-anti-TG2 are often 
found in patients with CD and are used in the diagnosing of CD and dermatitis 
herpetiformis (DH) patients (Husby et al 2012; Salmi et al 2013). Data on the 
pathogenesis of DH has revealed epidermal transglutaminase (TG3), an enzyme 
very similar to TG2, as the major autoantigen in DH (Sárdy et al 2002; Hull et 
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al 2008). IgA type antibodies against TG3 (IgA-anti-TG3) develop in patients 
with DH and precipitate as immune complexes in the papillary dermis, playing 
a role in skin lesion pathogenesis (Sárdy et al 2002; Hull et al 2008). On the 
other hand, mutations in the coding gene of another epidermal transglutaminase, 
keratinocyte transglutaminase (TG1), have been reported to be deficient in 
lamellar ichthyosis, a disease with severely impaired epidermal barriers (Eckert 
et al 2005). 
Both epidermal transglutaminases, TG3 and TG1, are expressed in the 
spinous and granular layers of the epidermis and are shown to have a role in 
epidermal barrier dysfunction as well as in barrier repair (Eckert et al 2005; 
Hitomi et al 2005). These proteins have been expressed in high concentrations 
in the skin of AD patients, especially in skin lesions (Cheng et al 2009; Liedén 
et al 2012). Also, humoral responses against TG3 have been shown in sera of 
CD patients as well as in DH patients (Borroni et al 2013). 
As dysfunction of the epidermal barrier and autoimmunity are relevant in the 
pathogenesis of AD, and transglutaminases have been shown to have a role in 
epidermal barrier function, we could suspect that circulating IgA-anti-TG3 and 
IgA type antibodies specific for TG1 (IgA-anti-TG1) may play a role in 




3. AIMS OF THE STUDY 
The general aim of the study was to investigate the incidence of CD in Estonian 
children and prevalence in children with AD and to find the clinical and 
immunological characteristics of coexistence of AD and CD. 
 
Accordingly, the specific aims were: 
1. To find the incidence of CD in children in Estonia and to analyse the trends 
in the incidence and clinical presentation. 
2. To find the prevalence of CD in children with AD and to characterise the 
clinical features of concomitant manifestation of AD and CD. 
3. To assess the general autoimmune background in children with AD by ANA 
determination and to evaluate clinical differences between ANA-positive 
and ANA-negative AD patients. 
4. To detect the presence of IgA type antibodies against TG1 and TG3 in the 
serum of children with AD, children with CD and children without known 
autoimmune or inflammatory disease, and to assess the potential role of 
these antibodies in AD.  
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4. MATERIAL AND METHODS 
4.1. Study subjects 
The general characteristics of study groups are described in Table 2. All serum 
samples were stored at minus 20C or lower degree until use. 
 
Table 2. Characteristics of study groups. 
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35-year study 









































sera (n=28) VI 
Study controls 
(n=117) 












sera (n=56) V, VI 















* – median age used instead of mean age. 
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Written informed consent was obtained from all studied patients or their 
parents. The studies were performed in conformance with the Declaration of 
Helsinki ethical guidelines and were approved by the Ethics Review Committee 
on Human Research of the University of Tartu, Estonia.  
 
4.1.1. Study subjects for investigating prevalence of CD  
in schoolchildren in Estonia (Paper I, II) 
In Paper I, the aim was to investigate the prevalence of CD in children 
population. Coded sera from 1160 randomly selected Estonian schoolchildren 
aged 9 and 15 years (median age 14.5 years, 54.8% females) were obtained 
from the European Youth Heart Study sample, collected in 1998–1999 in Tartu 
County (Harro et al 2001). In the original study, 25 schools were randomly 
selected using a probability proportional to the school size, and all children in 
grades III and IX were invited to participate based on the school registry. 
In Paper II, rescreening for CD was carried out in the same population after a 
ten-year period. In 2007–2008, coded sera were obtained from follow-up 
sampling of the same sample from the European Youth Heart Study. Of the 
previously studied patients, 891 were located and agreed to participate (median 
age 24.3 years, 56.4% females), for a participation rate of 76.8%. The follow-up 
sample well-represented the entire original sample from 10 years prior, in age 
and sex distribution. 
 
4.1.2. Study subjects for investigating incidence of CD  
in Estonia over a 35-year period (Paper III) 
Paper III analysed epidemiological data of all children up to 19 years of age 
newly diagnosed with CD according to the European Society for Paediatric 
Gastroenterology, Hepatology and Nutrition (ESPGHAN) diagnostic criteria 
from 1976 to 2010 in all of Estonia were analysed (n=152, mean age 4.9 years, 
range 0.4–18.0 years, 55.3% females)(Walker-Smith et al 1990).  
The earlier data collected by Oivi Uibo during 1976–2008 has been 
combined with the data collected during this study. In 1976–1989 data has been 
collected from hospital records retrospectively. Since 1990, all new CD cases 
have been recorded from two tertiary referral children’s hospitals in Estonia – 
Children’s Clinic of Tartu University Hospital and Tallinn Children’s Hospital 
– where all childhood CD cases are diagnosed in Estonia.  
Collected data included age at diagnoses, gender, symptoms at diagnosis, 
presence of associated conditions and data of histological investigations of 
small intestinal biopsy specimens. The clinical picture was defined as classical 
(diarrhoea with failure to thrive and/or weight loss), atypical gastrointestinal 
(any gastrointestinal symptom without failure to thrive or weight loss), 
extraintestinal (all other symptoms outside the gastrointestinal tract) or silent 
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presentation (asymptomatic, identified by testing because of associated 
condition, mainly type 1 diabetes, or by screening of first degree relatives) 
(McGowan et al 2009; Husby et al 2012). 
 
4.1.3. Study subjects for investigating CD  
in children with AD (Paper IV) 
Consecutive patients with active AD were recruited at Tallinn Children’s 
Hospital in 2008–2012. Active AD was diagnosed in clinically symptomatic 
children based on clinical history, objective findings and in accordance with the 
UK Working Party's Diagnostic Criteria for Atopic Dermatitis (Williams et al 
1994). In total, 351 patients with AD agreed to participate in the study (mean 
age 5.8 years, range 0.5–18.8 years, 42.4% females). Sera from children with 
AD were used for determining the prevalence of CD among AD patients.  
Serum samples were collected from all patients for antibody analysis. Based 
on clinical suspicion and/or seropositivity for IgA-anti-TG2, a small intestinal 
biopsy was offered to categorise the intestinal mucosal state by Marsh 
classification and to confirm the diagnosis of CD (Marsh 1992).  
Associated diseases and conditions were found in 121 AD patients: allergic 
rhinitis or rhinoconjunctivitis in 91 (25.9% of 351 AD patients), asthma in 57 
(16.2%), urticaria in 36 (10.3%), juvenile arthritis in 2 (0.7%), and type 1 
diabetes in one (0.3%).  
Prevalence of CD in AD patients was compared to prevalence of CD in 1160 
randomly selected Estonian schoolchildren, characterised in Paper I. 
 
4.1.4. Study subjects for investigating antinuclear  
antibodies in AD (Paper V) 
For assessing general autoimmune background in AD patients, serum samples 
from 346 patients with AD (excluding patients with concomitant CD) were 
analysed (mean age 5.8 years, range 0.5–18.8 years, 41.9% females). The 
patients were classified as having extrinsic or intrinsic types of AD based on 
clinical phenotype (defined by total IgE levels, allergen sensitisation and 
association with allergic asthma or rhinoconjunctivitis). The severity of AD was 
assessed based on patient medical files and was classified as mild (<3 points) or 
moderate/severe (3–9 points) based on Three Item Severity scoring 
(Wolkerstorfer et al 1999).  
Sera in the control group (n=117, mean age 7.9 years, range 0.5–17.7 years, 
44% females) were collected at Tallinn Children’s Hospital (n=56) and at 
Children’s Clinic of Tartu University Hospital (n=61) from children who had 
been hospitalized with various gastrointestinal, urological and other complaints 
for investigations but revealed to have no inflammatory or autoimmune 
diseases. Acute infection in study subjects was excluded using C-reactive 
protein and white blood cell count. 
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4.1.5. Study subjects for investigating antibodies against  
epidermal transglutaminases (Paper VI) 
For assessing the prevalence and role of IgA-anti-TG1 and IgA-anti-TG3 in 
Paper VI, serum samples of four different study groups were analysed – 
children with AD, children with AD and concomitant CD, children with CD and 
group of children with biopsy confirmed normal small intestinal mucosa. 
In this study, serum samples of 304 patients with only AD (mean age 5.5 
years, 43% females) and 5 patients with AD and concomitant CD (mean age 5.6 
years, 4 females) were analysed. Serum samples were collected as described in 
section 4.1.3.  
Serum samples of 28 patients with CD (mean age 6.2 years, range 1.0–16.5 
years, 64% females) were collected from patients diagnosed with CD according 
to ESPGHAN diagnostic criteria and in whom small intestinal biopsy 
specimens have been examined according to the Marsh classification (Walker-
Smith et al 1990; Marsh 1992). Patients were recruited from Tallinn Children’s 
Hospital (n=9) and Children’s Clinic of Tartu University Hospital (n=19). The 
clinical presentation of CD was defined as classical, atypical gastrointestinal, 
extraintestinal or silent type (Marsh 1992). Sera were collected at the same time 
as or up to one month prior to the small intestinal biopsy.  
For this study serum samples of 55 patients from study control groups with 
biopsy confirmed normal small intestinal mucosa, who had undergone 
gastroscopy for various functional gastrointestinal symptoms at Tallinn 
Children’s Hospital, were available (mean age 9.2 years, range 0.5–16.0 years, 
51% females). Patients presented predominantly with recurrent abdominal pain 
(58.9%), failure to gain weight (23.2%) or to thrive (17.8%), diarrhoea (17.8%) 
and abdominal bloating (16.1%). Asthma was found in 5 patients (8.9%). Acute 
infection in study subjects was excluded using C-reactive protein and white 
blood cell count determinations. Sera were collected at the same time as or up to 
one month prior to the small intestinal biopsy.  
 
 
4.2. Methods used for antibody analysis 
4.2.1. Total IgA, total IgE and IgE type antibodies  
to food allergen panels 
For exclusion of IgA deficiency, all patients with AD, CD patients and study 
controls were tested for total IgA with chemiluminescence assay (Roche 
Diagnostics, Burgess Hill, England) and compared to age-specific reference 
values provided by the manufacturer.  
All patients with AD, 9 patients with CD (recruited at Tallinn Children’s 
Hospital) and 56 study controls with biopsy data were tested for total IgE with 
Roche Diagnostics, Burgess Hill, England; Siemens Healthcare Diagnostics Inc, 
Tarrytown, USA) and compared to age-specific reference values provided by 
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the manufacturer. In these patient groups, IgE type antibodies to food allergen 
panels fx5 (egg white, milk, fish, wheat, peanut, soybean) and fx20 (wheat, rye, 
barley, rice) were measured using ImmunoCAP Specific IgE assay (Thermo 
Fisher Scientific, Uppsala, Sweden). According to the manufacturer’s 
recommendations, values of 0.35 kU/l or more were considered positive. 
 
4.2.2. Antibodies to tissue transglutaminase and  
deamidated gliadin peptides 
IgA and IgG type anti-DGP (IgA-anti-DGP, IgG-anti-DGP) were measured by a 
fluoroenzyme immunoassay using the EliA Gliadin DP assay (Thermo Fisher 
Scientific, Uppsala, Sweden). According to the manufacturer’s recommen-
dations, values of 10 EliA U/ml or more were considered positive and values 
less than 7 EliA U/ml were considered negative. Borderline values between 7 
and 10 EliA U/ml were considered negative to make the results dichotomic for 
statistical analysis. 
IgA-anti-TG2 and IgG type anti-TG2 (IgG-anti-TG2) were measured by a 
fluoroenzyme immunoassay using the EliA Celikey assay (Thermo Fisher 
Scientific, Uppsala, Sweden). According to the manufacturer’s recommen-
dations, values of 10 EliA U/ml or more were considered positive, and values 
less than 7 EliA U/ml were considered negative. Borderline values between 7 
and 10 EliA U/ml were considered negative to make the results dichotomic for 
statistical analysis. 
 
4.2.3. Indirect immunofluorescence assay for detection  
of antinuclear antibodies 
Serum samples of AD patients (n=351), control group patients (n=117) and CD 
patients (n=9) were tested for IgG ANA by indirect immunofluorescence on 
Hep-2 cells using commercial kit of ImmunoConcepts (Sacramento, CA, USA) 
and serum dilutions starting from 1:10 in PBS (phosphate-buffered saline) 
(Uibo et al 1998). This serum dilution was the lowest that has been reproducibly 
used at our laboratory for ANA screening among paediatric populations (data 
not shown). Sera with ANA at titer 1:160 were tested for autoantibodies against 
extractable nuclear antigens Sm, RNP, SSA/Ro, SSB/La, Scl-70, and Jo-1 with 
enzyme immunoassay (RELISA ENA, ImmunoConcept, Sacramento, CA) and 
for double stranded DNA (dsDNA) by indirect immunofluorescence using 
Chritidia lucilia for substrate (Fluorescent nDNA Test System, Immuno-




4.2.4. IgA type antibodies to transglutaminase 1 and 3 
IgA-anti-TG1 and IgA-anti-TG3 were measured by enzyme-linked 
immunosorbent assay (ELISA) as described earlier (Teesalu et al 2009) using 
recombinant TG1 and TG3 as target antigens (Zedira GmbH, Darmstadt, 
Germany). Universal binding 96-well microtiter plates (Thermo Fisher 
Scientific, Vantaa, Finland) were coated with 0.5 μg TG1 or TG3 per well in 
100 μl TBS-Ca buffer containing 25 mmol/l Tris-HCl, 150 mmol/l NaCl, 
5mmol/l CaCl2, (pH 7.4), and incubated overnight (16 h) at 4°C. Thereafter 
wells were washed five times with 300 μl TBS-TE buffer (25 mmol/l Tris-HCl, 
150 mmol/l NaCl, 10 mmol/l EDTA, 1 ml/l Tween 20, pH 7.4), and once with a 
solution of 50 g/l sucrose, 0.5 g/l thimerosal in TBS. After discarding solution, 
plates were dried at 20°C for 3 h, sealed, and kept at 4°C until use. Serum 
samples were diluted 1:100 in TBS-T buffer (25 mmol/l Tris-HCl, 150 mmol/l 
NaCl, 1 ml/l Tween 20, pH 7.4) and incubated in duplicate on TG coated wells 
for 1h. Incubations were performed at 20°C and followed by washing step with 
300 μl TBS-T five times. The wells were incubated with dilutions of alkaline 
phosphatase conjugated antibodies of goat anti-human IgA (Invitrogen) in TBS-
T buffer for 30 min. Incubations was performed at 20°C and followed by 
washing step with 300 μl TBS-T five times. The color reaction was developed 
by incubating the wells with 100 μl substrate 4-p-nitrophenyl phosphate (1 g/l) 
in 1 mol/l diethanolamine, 0.5 mmol/l MgCl2 (pH 9.8) for 30 min and stopped 
by adding 50 μl 0.1 mol/l EDTA. The absorbances were read at 405 nm with 
492 nm subtraction and the antibody levels expressed in arbitrary units (AU) as 
percentages of the reference serum optical density values. Reference values for 
IgA-anti-TG1 and IgA-anti-TG3 were calculated by determining the mean+2SD 
in control group patients with normal small intestinal mucosa (characterised in 
paper VI). Therefore IgA-anti-TG1 values of 37.3 AU or more and IgA-anti-
TG3 values of 48.4 AU were considered positive. 
 
 
4.3. Statistical analysis 
For statistical analyses, R software for Windows (The R Foundation for 
Statistical Computing, Vienna, Austria) and MedCalc statistical software 
(MedCalc Software, Mariakerke, Belgium) were used. Data were expressed as 
absolute numbers or proportions for categorical variables and as means for 
continuous variables. Comparison between proportions and means was carried 
out using parametric and non-parametric tests as appropriate. A p-value less 
than 0.05 was used to reject the null hypothesis.  
In Paper III, newly diagnosed cases were grouped according to their age at 
diagnosis in four groups: 0–4, 5–9, 10–14 and 15–19 years. Incidence rates (IR) 
for boys and girls of different age-groups and different calendar years at 
diagnosis are expressed as the number of new cases per 100 000 person-years 
using official mid-year population data for relevant age and sex groups from 
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Statistics Estonia. The 95% confidence interval (CI) for the incidence was 
estimated using the exact method based on the Poisson distribution. Bonferroni 
correction was used in multiple comparisons.  
In Paper VI, the diagnostic performance of assays in terms of sensitivity and 
specificity expressed as a percentage was calculated based on the cut-off values 






5.1. CD in children in Estonia 
5.1.1. Prevalence of CD in random population  
of schoolchildren in Estonia (Paper I, II) 
Serum samples from 1160 Estonian schoolchildren aged 9 and 15 years were 
studied for IgA-anti-TG2. Five of the 1160 sample showed elevated IgA-anti-
TG2 and were invited for follow-up studies. Four out of five, all non-relatives, 
agreed to participate and were again IgA-anti-TG2 positives and had the HLA-
DQ2 allele characteristic of CD. In all four, CD was confirmed by biopsy, 
yielding a CD prevalence of 1:290 (0.34%; 95% CI: 0.09–0.88%) (Table 3). 
Three of them had complaints and symptoms that might be attributable to CD 
but were not considered by their family doctors – a 9-year-old girl presented 
with iron deficiency anaemia and recurrent abdominal pain, two 15-year-old 
girls presented with failure to thrive. One 15-year-old girl had neither 
complaints nor symptoms for suspecting CD, despite subtotal villous atrophy of 
the small intestinal mucosa. 
 
Table 3. Data for subjects with positive IgA-anti-TG2 test results at screening and after 
follow-up. 
  Baseline screening  Second screening 



















1492 F 9 15.0 55.0 Marsh IIIc  18 1.8 Good 
1511 F 15 15.5 NA NA  NA NA NA 
1691 F 15 41.1 52.0 Marsh IIIb  25 23.7 Poor 
1873 F 15 22.6 38.5 Marsh IIIb  25 51.7 Poor 
2027 F 15 39.5 14.5 Marsh IIIb  25 14.0 Poor 
NA – not available for testing; 
*positive test results typed in bold. 
 
In the second screening of the same population after a 10-year period, three 
subjects had positive IgA-anti-TG2 results (Table 3). All three were also IgA-
anti-TG2 positive in the baseline screening and had biopsy-proven CD. Out of 
two other subjects who were initially seropositive at the first screening, one did 
not participate in the second study and the other with biopsy-verified CD has 
turned seronegative, as she had strictly followed the gluten-free diet during the 
follow-up years.   
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5.1.2. Incidence of CD in Estonia over  
a 35-year period (Paper III) 
During 1976–2010, a total of 152 children (median age 2.3 years, 68 boys and 
84 girls) were diagnosed with CD in Estonia. The overall incidence rate of CD 
was 1.12 per 100 000 person-years (95% CI: 0.94–1.31).  
During the study period of 1976–1989 only 13 children were diagnosed with 
CD, compared to 139 children in the period of 1990–2010. Thus, the incidence 
rate increased from 0.21 per 100 000 person-years in the period of 1976–1989 
to 1.85 per 100 000 person-years in the period of 1990–2010. A comparison of 
the general characteristics of the diagnosed cases is shown in Table 4. 
 
Table 4. General characteristics of new CD cases in the two study periods. 
 Period of  
1976–1989 
Period of  
1990–2010 
Cases  13 139 
Male / female ratio 1 / 3.3 1 / 1.1 
Incidence rate per 100 000 person years (95% CI) 0.21 (0.11–0.36) 1.85 (1.55–2.18) 
Median age at diagnosis (years) 1.0 3.0 
Age at diagnosis (n, %)   
     0–4 years 13 (100%) 78 (56%) 
     5–9 years 0 28 (20%) 
     10–14 years 0 26 (19%) 
     15–19 years 0 7 (5%) 
Clinical presentation of CD:   
     classical symptoms (n, %) 10 (77%) 55 (39%) 
     atypical GI symptoms (n, %) 3 (23%) 42 (30%) 
     extraintestinal symptoms (n, %) 0 12 (9%) 
     silent CD (n, %) 0 30 (22%) 
 
Our analyses shows that the annual incidence rate was 0.10 per 100 000 person-
years (95% CI: 0.01–0.34) during 1976–1980 and showed remarkable increase 
to 3.14 per 100 000 person-years (95% CI: 2.29–4.18) in 2006–2010. The 
changes can be associated with the start of an active clinical search for CD, 
introduction of the gliadin antibody and/or EmA screening in 1990, introduction 
of anti-TG2 to routine clinical practice in 2003, and start of a CD screening 





Figure 1. Distribution of CD incidence rate per 100 000 person years during 5 year 
periods. A – active clinical search for CD and introduction of gliadin antibody and/or 
EmA screening to clinical practice; B – introduction of anti-TG2 to routine clinical 
practice; C – introduction of CD screening among all children with type 1 diabetes. 
 
 
In the period of 1990–2010, there was a significant increase in the median age 
of the patients from 1.0 in the earlier study period to 3.0 (p < 0.001; Figure 2). 
In 1976–2000 73.6% of cases were diagnosed before the age of five. The age-
specific incidence rate in the older age groups showed largest increase during 
the period from 2006–2010. In the latter group, 71.7% of the cases were 
diagnosed after the age of five.
Figure 2. Distribution of incidence rate per 100 000 person-years according to the age-






Distribution of new CD cases according to clinical presentation at 
 
the time of 
During the study period, most of the cases (42.8%) were diagnosed in children 
with a classical clinical presentation (diarrhoea with failure to thrive or loss of 
weight). From 1976–1989, all new cases were diagnosed under the age of five 
years with either a classical (76.9%) or atypical gastrointestinal clinical 
presentation (23.1%). In contrast, during the years 2006–2010, silent clinical 
presentation was documented in 43.5% of the cases (Figure 3).
Associated diseases and conditions were documented in 104 patients out of 152 
CD patients, including predominantly type 1 diabetes (33 patients, 22%), rickets 
(13 patients, 9%), Down syndrome (9 patients, 6%) and AD (8 patients, 5.3%). 
Concomitant iron deficiency anaemia was found in 30 patients (20%) and 
elevated transaminases were noted in 10 patients (7%). Less than 3% of patients 
had other chromosomal diseases, DH, osteoporosis, epilepsy or herpetic 
stomatitis. 
All diagnosed CD cases were regionally classified according to the place of 
residence at diagnosis. The incidence rate of CD for all regions of Estonia from 
1976–2010 was 1.12 (95% CI: 0.94–1.31). The incidence rates for CD in 
Jõgeva County (IR 2.46; 95% CI: 1.18–4.53) and Järva County (IR 2.14; 95% 
CI: 0.98–4.07) were more than twice as high as the incidence rate for the whole 




Figure 4. Incidence rate of childhood CD in Estonian counties from 1976–2010. The 
two referral hospitals are marked with diamonds. 
 
 
Altogether 351 children with AD were screened for CD, and CD was diagnosed 
in 5 of them (1.4%; 95% CI: 0.46–3.32) (Table 5).  
For exclusion of IgA deficiency, all patients were tested for total IgA. 
Deficiency of IgA was diagnosed in 9 (2.6%) patients with AD, but none of 
them had seropositivity for CD-associated antibodies, IgG-anti-TG2 or IgG-
anti-DGP. 
IgA-anti-DGP were found in 11 (3.1%) AD patients (3 of them also IgA-
anti-TG2 positive), and IgG-anti-DGP were found in 10 AD patients (2.8%) (4 
of them also IgA-anti-TG2 positive). IgA-anti-TG2 positivity was found in 4 
(1.1%) of AD patients, and IgG-anti-TG2 positivity in 2 (0.6%) of AD patients 
(both positive for IgA-anti-TG2). 
Among the four female IgA-anti-TG2 positive patients, all were positive for 
IgG-anti-DGP, while 3 were positive for IgA-anti-DGP and 2 were positive for 
IgG-anti-TG2. Based on clinical suspicion or seropositivity, small intestinal 
biopsy was performed in 13 patients. CD was confirmed in 4 patients with IgA-
anti-TG2 positivity, showing villous atrophy and severe crypt hyperplasia. CD 
was also diagnosed in a 1.2 years old boy with high clinical suspicion based on 
pronounced chronic intermittent diarrhoea but no reactivity for any tested 
autoantibody. Histological analysis of small intestinal mucosa showed villous 
atrophy and increased crypt hyperplasia (Marsh IIIa).  



































































































































































































































































































































































































































































































































































































































































































































In the rest of IgA-anti-DGP and IgG-anti-DGP positive patients, CD was not 
diagnosed, because of lack of clinical suspicion, normalisation of analysis in 
follow-up sampling or normal small intestinal histology. One patient (Table 5, 
TT061) with IgA-anti-DGP underwent small intestinal biopsy because of 
abdominal pain, but revealed normal intestinal histology. Five patients showed 
normalisation of IgA-anti-DGP and/or IgG-anti-DGP on follow-up visitation 
with their treating physician and in six patients the only slightly elevated 
antibody levels were considered clinically non-relevant, therefore small 
intestinal biopsy was not performed. 
 
 
5.3. Antinuclear antibodies in AD (Paper V) 
For assessing general autoimmune background 346 patients with AD (excluding 
patients with AD and concomitant CD) and 117 study control group patients 
were studied.  
Total-IgE levels were elevated in 59.5% of patients with AD, and 44.2% had 
allergen-specific IgE to food allergens. No statistically significant difference in 
ANA-positivity was noted between patients with elevated and normal total-IgE 
levels (15.0% and 11.4% respectively). Also, despite significant differences in 
sensitisation rate to different allergen panels in AD patients (p<0.05), no 
remarkable differences were observed in ANA-positivity between sensitisation 
to different allergen panels. 
From studied AD patients, 29.8% could be classified as having intrinsic type 
of AD (normal IgE levels, no allergen-specific IgE and no association with 
allergic respiratory diseases), and 70.2% had extrinsic type of AD (Table 6). 
ANA was found to be positive in 10 patients with intrinsic AD (9.7%) at titers 
up to 1:80 and in 37 patients with extrinsic AD (15.2%) at titers up to 1:160. 
Although the rate of ANA-positivity at titer 1:10 was slightly higher in extrinsic 
type of AD patients than in intrinsic type, the difference was not significant (OR 
1.7; 95% CI 0.80–3.50). 
Based on severity of AD symptoms, 69 (19.9%) of the patients with AD 
could be classified as having moderate or severe form of AD. ANA positivity 
was found more frequently in mild form of AD (14.8%) when compared to 
moderate or severe form (8.7%), but the difference was not statistically signi-
ficant. 
In total, 47 patients with AD (13.6%) and 15 patients (12.8%) from the 
control group were positive for ANA, with mostly homogenous or speckled 
fluorescent pattern (Table 7). Compared to the control group, ANA was found 
at slightly higher titres in AD patients. Only AD patients had ANA at titre 
1:160, all of them presented with extrinsic type of AD and with no clinical signs 
or symptoms for systemic autoimmune diseases.  
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Table 6. Characteristics of AD patients (n=346). 
 Extrinsic type of AD Intrinsic type of AD 
Number (%) 243 (70.2%) 103 (29.8%) 
Mean age 6.2 years 4.8 years 
Male gender 145 (59.7%) 56 (54.4%) 
Elevated total IgE 
(>age related reference) 
206 (84.8%) 0 
Mean total IgE 420.7 kU/l 22.3 kU/l 
Specific IgE to panel fx5 (>0.35 kU/l) 
(egg white, milk, fish, wheat, peanut, soybean) 
140 (40.5%) 
Specific IgE to panel fx20 (>0.35 kU/l) 
(wheat, rye, barley, rice) 
67 (19.4%) 
ANA 1:10 positive 37 (15.2%) 10 (9.7%) 
 
 
Table 7. ANA pattern in AD patients and study controls. 
 ANA titer 
 1:10 1:40 1:80 1:160 








     homogenous, n 33 19 11  1* 
     speckled, n 8 4 3  1* 
     few nuclear dots, n 5 4 3    1** 
     nucleolar, n 1 1 0 0 
     







     homogenous, n 10 5 2 0 
     speckled, n 3 2 0 0 
     few nuclear dots, n 2 2 2 0 
*  additionally tested for extractable nuclear antigens and dsDNA, no positivity; 
**  additionally tested for extractable nuclear antigens and dsDNA, weak positive reaction to 








Figure 5. Mean age in AD and control patients based on ANA-positivity at titre 1:10. 
The mean age differed significantly between ANA-negative and ANA-positive patients 
in AD group (5.4 vs 8.2 years; p<0.005), but not in control subjects (7.7 vs 9.1). 
 
 
For assessing the prevalence and role of IgA-anti-TG1 and IgA-anti-TG3, 
serum of children with AD (n=304), children with AD and concomitant CD 
(n=5), children with CD (n=28) and study control children with normal small 
intestinal mucosa were investigated (n=55).  
Due to IgA deficiency in the current study groups, 7 (2%) of the studied AD 
patients and 3 (5%) of study control patients were excluded from further 
antibody and statistical analysis, leaving 297 AD patients and 52 study controls 
for the statistical analysis of this study. Antibody responses to TG2 and 
epidermal transglutaminases (TG1 and TG3), together with IgA-anti-DGP in 
different study groups are shown in Table 8. 
ANA was found significantly more often in female than in male AD patients 
(OR 3.5; 95% CI: 1.8–6.8). On the other hand, there was no significant 
difference in odds for ANA-positivity based on gender in control subjects.  
In AD patients, ANA was noted already at the age of 2 years, whereas in 
controls, ANA was not found before the age of 4.6 years. Although the mean 
age of ANA-positive patients in the AD group was slightly younger than in the 
control group (8.2 vs 9.1 years), the difference was not statistically significant. 
However, the mean age in the AD group differed significantly between ANA-
positive and ANA-negative AD patients at titres up to 1:40 (8.2 vs 5.6 years; 
p<0.005). No significant difference in mean age was noted based on ANA-












Table 8. Seropositivity rates in different patient groups (IgA deficient cases excluded). 
 IgA-anti-TG1  IgA-anti-TG2 IgA-anti-TG3 IgA-anti-DGP 






































































 AD vs controls p=0.340 
AD vs CD p=0* 
AD vs AD+CD p=0.006 
AD+CD vs controls p=0.035 
AD+CD vs CD p=1 
CD vs controls p<0.005 
 AD vs controls p=0.149 
AD vs CD p=0 
AD vs ADCD p=0 
AD+CD vs controls p<0.005
AD+CD vs CD p=0.284 
CD vs controls p=0 
 AD vs controls p=0.671 
AD vs CD p<0.005 
AD vs AD+CD p=1 
AD+CD vs controls p=1 
AD+CD vs CD p=0.569 
CD vs controls p=0.048 
 AD vs controls p=0.628 
AD vs CD p=0 
AD vs AD+CD p<0.005 
AD+CD vs controls p<0.005 
AD+CD vs CD p=0.216 
CD vs controls p=0 
* p values marked in bold are statistically significant. 
 
In the AD group, 7 patients (2%) had slight IgA-anti-DGP reactivity, all were 
>2 years of age and none were seropositive for other markers. Six patients with 
AD (2%) had elevated IgA-anti-TG1 and 9 patients with AD (3%) had elevated 
IgA-anti-TG3, all of them were IgA-anti-TG2 negative. 
Of the 5 AD patients with concomitant CD, 4 had IgA-anti-TG2 and 3 had 
IgA-anti-DGP antibodies. Two AD and concomitant CD patients with positive 
IgA-anti-TG1 responses also had IgA-anti-TG2 and IgA-anti-DGP responses 
(Table 5, AT018 and AT091).  
IgA-anti-TG2 was identified in 27 (96%) and IgA-anti-DGP identified in 24 
(86%) CD patients (all these 24 were also positive for IgA-anti-TG2). Out of 28 
CD patients 10 (36%) showed IgA-anti-TG1 and 5 (18%) showed IgA-anti-TG3 
responses. All of them were also IgA-anti-TG2 positive and most of them also 
IgA-anti-DGP positive. 
In the control group, only 1 patient presented with borderline IgA-anti-TG2 
values without any accompanying seropositivity. Elevated IgA-anti-DGP values 
were found in the sera of 2 control group patients, both <2 years of age and 
without other detectable autoantibodies. No changes to the small intestine 
mucosa were identified in these 3 patients (Marsh 0). Elevated IgA-anti-TG1 
and IgA-anti-TG3 levels were also found in 3 control group patients (4%), none 
of whom had elevated IgA-anti-TG2 levels. One patient presented with long-
lasting diarrhoea and cystic fibrosis, and two patients with acute gastritis 
resulting from a Helicobacter pylori infection; all of them presented with 
normal small intestinal mucosal histology (Marsh 0). 
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Seropositivity rate and mean antibody levels of IgA-anti-TG1 and IgA-anti-
TG3 were higher in CD patients (mean antibody levels 48.3 and 67.0 AU 
respectively) than among controls (mean antibody levels 14.5 and 18.7 AU) or 
AD patients (mean antibody levels 9.5 and 13.7 AU) (Figure 6). In AD patients 
with concomitant CD, IgA-anti-TG1 responses were as prevalent as in the CD 
patients but more common compared to controls (p<0.05) or AD patients 
(p<0.005), indicating that IgA-anti-TG1 and IgA-anti-TG3 responses were 
associated with CD and not with AD.  
 
     
Figure 6. IgA-anti-TG1 (A) and IgA-anti-TG3 (B) values in the different patient 
groups. 
AD, atopic dermatitis; CD, coeliac disease;  
* Horizontal line – reference value based on the mean +2SD of the control subjects. 
 
Elevated IgA-anti-TG1 and IgA-anti-TG3 levels were found in 6 and 9 AD 
patients, respectively, whereas only 1 patient with AD had both elevated IgA-
anti-TG1 and IgA-anti-TG3 antibody levels. On the other hand, patients 
presenting with CD or with AD and concomitant CD tended to be seropositive 





6.1. CD in children in Estonia  
6.1.1. Prevalence of CD  
Until 1990 CD was considered a very rare disease in Estonia. Retrospective 
analysis of all childhood CD cases in Estonia by Uibo et al revealed 0.04 new 
CD cases per 1000 live births in 1976–1990. In 1990–1994, Uibo et al carried 
out an active clinical search and serological screening for CD that in 
conjunction with regular educational activities (e.g., seminars and lectures, 
postgraduate courses, publications) for physicians has led to a marked increase 
in the detection of new CD cases in Estonia (0.37 cases per 1000 live births). 
Still, the rate remained approximately ten times lower compared to other 
countries (Uibo 1994a; Uibo 1994b; Uibo et al 1996). In addition, Uibo et al 
have screened 1939 persons from the general population including 1461 adults 
in 1990 and 478 schoolchildren in 1998, finding no new cases of CD (Uibo et al 
1993; Metsküla et al 1998).  
In present study we have expanded these investigations by screening 1160 
randomly selected schoolchildren and have found the prevalence of CD at least 
1 case per 290, i.e. 0.34% (95% CI 0.09–0.88) for Estonia, showing significant 
increase in prevalence. We believe that the increase in CD prevalence represents 
the real prevalence of CD and is not caused by difference of the screening 
method. The latter reason is unlikely as the combination of antigliadin and 
antireticulin antibody assays (used by Uibo et al) has been shown to be highly 
effective in detecting CD, although somewhat inferior to IgA-TGA assay (used 
in this study) regarding sensitivity (Rubio-Tapia et al 2009; Kagnoff 2005). 
In recent years, several population screening studies have shown upward 
trends, especially among the younger age groups (Heel et al 2006; Lohi et al 
2007; Olsson et al 2008; Vilppula et al 2009). Therefore we expected to find 
new CD cases after the 10-year interval, however follow-up sampling of the 
same population revealed no new antibody-positive cases in the rescreening of 
891 children. The relatively high median age may have influenced the study 
outcome as CD tends to develop more frequently in children. In support, Mariné 
et al has found five times higher prevalence in children when compared to 
adults (Mariné et al 2011). On the other hand, the size of our study sample and 
length of follow-up period could have been insufficient for finding actual rate of 
new cases. 
Our findings about the prevalence of CD in Estonia differ noticeably from 
results from Finland and Sweden, where CD was detected in up to 3% of the 
children, indicating the possibility of a major environmental difference between 
these countries (Ivarsson et al 2000; Mäki et al 2003; Kondrashova et al 2008; 
Olsson et al 2008; Myléus et al 2009). Underlying causes for the difference in 
CD incidence these neighbouring countries might include previously shown 
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different microbial load in Estonian and Swedish populations, increase in the 
intake of disease-inducing gluten and other prolamines, together with awareness 
of CD among physicians (Björkstén et al 1999; Böttcher et al 2003; Kagnoff 
2005; Rubio-Tapia et al 2009; Vilppula et al 2009; Ivarsson et al 2013). In 
addition, the influence of genetic and environmental factors on the incidence of 
CD in the Estonian population compared to other European populations and 
other age groups requires further investigation.  
 
6.1.2. Trends in the incidence and  
the clinical presentation of CD 
In this study, analysing the hospital data, we have demonstrated a dramatic 
nationwide increase in the incidence of CD among children in Estonia during a 
35-year period. Up to 1990, no remarkable changes were noted in the incidence 
rate of CD. On average, one new case per year was noted in Estonia. After the 
introduction of gliadin antibody and/or EmA screening methods into routine 
clinical practice in 1990 and active clinical searches for CD, especially in high 
risk groups, the incidence rate increased substantially. Several studies have 
shown high rate of undiagnosed CD in different countries, indicating the need 
for raising awareness of variable clinical patterns of CD and probably indicating 
the need for screening special risk groups (Myleus et al 2009; Norström et al 
2011). Therefore, the increase in the prevalence of clinically detected CD in 
Norway and South Wales is probably related to high awareness of the disease in 
these countries (Størdal et al 2013; Whyte and Jenkins 2013). 
In addition to the impact of introducing routine CD screening methods and 
active clinical search for CD, activities directed to increase the physicians’ 
awareness (started in 1990) may have had strong effect on increasing the 
incidence of CD in Estonia. Unfortunately, during some intervening periods, the 
detection rate of CD decreased, emphasising the need for continuous and active 
awareness programs.  
During 1976–1989, all newly diagnosed cases presented either with the 
classical clinical symptoms of CD or with atypical gastrointestinal symptoms, 
and the median age at diagnosis was 1.0 year. The introduction of active clinical 
searches for CD and introduction of the gliadin antibody and/or EmA screening 
in 1990 and introduction of anti-TG2 to routine clinical practice in 2003 
together with anti-TG2 screening among all children with type 1 diabetes in 
2005 led to a significant increase in the prevalence of CD together with more 
than a 6-fold increase in the median age of patients diagnosed with CD. Our 
results confirm the shift towards atypical symptoms and older age diagnosis, as 
reported previously for other countries (Roma et al 2009).  
Associated disease and conditions were found in 68% of patients with CD – 
type 1 diabetes, iron deficiency anaemia, chromosomal diseases (including 
Down syndrome), rickets, AD and concomitant elevated transaminases were 
frequently observed. Rickets was associated with classical gastrointestinal 
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symptoms and was diagnosed only during the first period of study (1976–1989). 
Most commonly CD was associated with type 1 diabetes (22%), but AD was 
revealed in 5.3% of all registered CD patients. Our findings are in accordance 
with other reports, as CD has been often associated with other autoimmune and 
inflammatory diseases as well as with atopy (Elli et al 2012; Reilly et al 2012; 
Iwańczak et al 2013). 
In addition to the rising awareness of CD, a real rise in the incidence rate of 
CD could have taken place, with difference in microbial load as one of the 
possible reason. In western industrialised countries, people mainly consume 
industrially processed food, but the Estonian diet is still largely composed of 
locally produced foods and various lactic acid fermented products. However, 
over the last decades (after regaining national independence in 1991), there have 
been remarkable changes in the state of the economy and dietary habits in 
Estonia. Increased consumption of wheat and use of gluten in food processing, 
together with the introduction of wheat varieties with increased CD toxicity 
may have an impact on the incidence of CD (van den Broeck et al 2010). Still, 
based on Eurostat database (http://epp.eurostat.ec.europa.eu/), during 2000–
2009 the apparent average wheat consumption per capita was three times lower 
in Estonia (51 kg/head) than in Italy (157 kg/head), probably leading to a lower 
incidence of CD in Estonia compared to Italy (Volta et al 2001). 
Additionally, infant feeding practices (introducing wheat containing 
products at an earlier time and in higher amounts), together with socioeconomic 
factors may attribute to the differences in the CD incidence rate between 
Estonia and other countries. In 1998, when Estonia belonged to the group of 
countries with very low prevalence of CD, Mitt and Uibo demonstrated that 
there is a low cereal intake in Estonian infants compared to Finnish and 
Swedish infants, and the mean wheat intakes in infants at the age of 12 months 
were 23 g, 23.3 g, and 49 g per day, respectively (Mitt et al 1998). Un-
fortunately, we have no later comparative investigations on this important topic. 
There are studies showing increased risk for CD among people of a lower 
socioeconomic status (Ivarsson 2005; Wingren et al 2012) and also studies 
showing increased risk among those with higher socioeconomic position (Olén 
et al 2012; Whyte and Kotecha et al 2014). According to data from Statistics 
Estonia, Jõgeva and Järva counties belong to the group of counties with higher 
unemployment rates during the last decade. A lower income together with other 
socioeconomic factors might dispose people to an earlier introduction and 
higher consumption of complementary cereals (i.e., wheat) due to their low 
cost. The relatively higher incidence rates of CD in these counties could 
therefore be at least partly explained by their lower socioeconomic status. 
Therefore, introduction of serological screening methods, active clinical 
search and raising awareness among physicians have increased the detection 
rate of CD in Estonia. However, true increase in incidence may have also 
occurred together with a shift towards older age and atypical clinical pre-
sentation. 
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6.2. CD in children with AD  
Previous studies have shown increased prevalence of CD in different atopic 
disorders (Zauli et al 2000). However, results about CD prevalence in AD 
patients have been controversial, probably due to small cohort sizes and 
different inclusion criteria (Gallo et al 1992; Uibo et al 1996). We have studied 
patients with AD with active clinical cutaneous manifestations, as in chronic 
eczematous lesions Th1 type responses play a major role in addition to the 
earlier phase of Th2-mediated responses (Bieber 2008). As exogenous allergens 
play a role in AD and in case of chronic active allergic inflammation, it might 
be speculated that chronic ingestion of allergens may lead to tissue damage of 
the gut epithelial cells and therefore expose possible autoallergens. 
Screening of 351 children with AD led to diagnosing CD in 5 (1.4%; 95% 
CI: 0.46–3.32) children. Three patients (1.2-year-old boy, 10.8-year-old girl and 
5.5-year-old girl) presented with pronounced (typical) gastrointestinal symp-
toms (chronic/episodic diarrhoea, abdominal distension, recurrent abdominal 
pain), with small intestinal histological studies showing at least partial villous 
atrophy (Marsh IIIa–IIIc).  
However, two female AD patients (6.9 and 3.5 years old) newly diagnosed 
with CD were totally asymptomatic for CD, but histological studies showed 
subtotal/total villous atrophy at the small intestinal mucosa level (Marsh IIIb 
and IIIc respectively). These cases clearly illustrate challenges of diagnosing the 
atypical or silent forms of CD in AD. 
When screening the randomly selected population of schoolchildren in our 
earlier study (Paper I), we found CD in 0.34% of the general children 
population (95% CI: 0.09–0.88). Based on our results, the risk for developing 
CD is more than four times higher in AD patients when compared to the general 
children population (OR=4.18; 95% CI: 1.12–15.64). 
Difference in mean ages of AD patients and schoolchildren population could 
have biased our comparison, as the mean age of randomly selected 
schoolchildren is remarkably higher than that of AD patients (14.5 vs 4.3 years 
respectively). However, as CD incidence tends to increase with age, one could 
expect higher prevalence of CD in older study group (i.e. random school-
children population) instead.  
Deficiency of local immune response and low IgA levels have been 
associated with higher prevalence of autoimmune and allergic diseases 
(Hodgson et al 1976; Aghamohammadi et al 2009). In this study of 351 AD 
children, IgA deficiency was found in 2.6% patients: that is twelve times higher 
prevalence than in the Estonian general population (0.2%)(Velbri et al 2005). 
As IgA has major role in providing immune responses at the mucosal level, IgA 
deficiency, together with recurrent infections, may lead to inflammation at the 
mucosal level. On the other hand, permeability of intestinal mucosa has shown 
to increase both in CD and AD (Williams 1987; Walker-Smith et al 1990; 
Marsh 1992). Therefore, IgA deficiency, inflammation at the mucosal level and 
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increased permeability of intestinal mucosa may play a role in determining the 
passage of autoantigens through the intestine and channel the comanifestation 
of CD and AD. However, in our study, CD was not detected in any of the AD 
patients with IgA deficiency.  
In autoimmune and allergic diseases, a major role for pathogenesis has been 
admitted to dysregulation of immune responses, suggesting a defect in the 
function of regulatory T cells (Treg) (Banham et al 2006; Taams et al 2006). 
Evidence suggests a role for Treg in the pathogenesis of both diseases  CD and 
AD. In several autoimmune diseases CD4+CD25+ Treg from peripheral blood 
were found to have reduced capacity to suppress T-cell proliferation and IFN-γ 
production. A study by Vorobjova et al showed increased FOXP3 expression in 
small intestinal mucosa of children with CD and type 1 diabetes (Vorobjova et 
al 2009). Ito et al have shown that percentages of circulating FOXP3+CD25+ 
Treg are higher in AD patients than in controls and correlate with the activity of 
the disease (Ito et al 2009). However, these cells are unable to leave the 
circulation and enter the skin, therefore resulting in the exaggerated cutaneous 
inflammatory response characteristic of AD (Verhagen et al 2006; Ito et al 
2009). Hence, the defect of mucosal barrier together with dysregulated immune 
response may play a role in the coexistence of AD and CD. Future studies are 
needed to evaluate the role of FOXP3+CD25+ Treg in the intestinal mucosa of 
patients with concomitant AD and CD. 
 
 
6.3. Autoimmune reactions in children with AD 
Several studies have suggested that autoimmune mechanisms play a role in the 
development and progression of AD and IgE-mediated autoreactivity is 
significantly associated with persistence of eczema and the presence of impaired 
skin barrier and food allergy (Valenta et al 1999; Mothes et al 2005). High 
percentages of AD patients have been reported to have autoreactivity towards a 
broad spectrum of human proteins, and that has been shown to increase during 
exacerbations of skin inflammation (Wolkerstorfer et al 1999; Mittermann et al 
2004; Szakos et al 2004). Autoimmune processes may play a pathogenic role in 
severe and chronic forms of atopy (Valenta et al 2009). 
 
6.3.1. General autoimmune background of AD 
Among autoimmune markers, antibodies against different common components 
of cells have been widely used for detection of general autoimmune propensity 
and background in various diseases. Among many candidates, autoantibodies to 
nuclear proteins and protein complexes, collectively called ANA, have received 
considerable attention in many diseases (Agmon-Levin et al 2014). ANA-
positivity in AD patients has varied widely in earlier reports, some of them 
showing remarkable difference and others, no significant difference in the 
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prevalence of ANA between AD and control patients (Williams et al 1994; 
Ohkouchi et al 1999; Higashi et al 2009; Tang et al 2012). We found low titer 
ANA in children with AD at the frequency (13.6%) comparable to the control 
group (12.8%).  
Although most of our studied patients with AD belonged to extrinsic form of 
AD (70.2%) and the rate for ANA-positivity was somewhat higher in this group 
of patients, there was no statistical difference of ANA-positivity between 
patients with intrinsic and extrinsic type of AD. Although we found ANA-
positivity slightly more frequently in AD patients with elevated serum IgE 
levels (15.0%) when compared to patients with normal total-IgE levels (11.4%), 
there was no statistically significant difference. However, increased total-IgE 
levels have been associated with increased prevalence of IgE-autoreactivity, and 
the latter may perpetuate allergic inflammation (Tang et al 2012). 
We found ANA more often in female than male patients, and the difference 
could probably be explained by the overall tendency for autoimmunity in 
females, but also by the higher age of females in our study group. As the 
prevalence of ANA generally tends to increase with older age, prevalence of 
ANA-positivity could be lower in younger patient groups. On the contrary, we 
found ANA-positivity in AD patients already at the age of 2 years, whereas in 
the control group, ANA was found at a remarkably older age. 
Although some earlier reports have shown higher prevalence and higher 
titres of ANA in more severe forms of AD, we did not find significant 
differences in relation to the overall severity of AD (Mothes et al 2005; Higashi 
et al 2009). We have found ANA at slightly higher titres in AD patients when 
compared to controls, with the fluorescent pattern being mostly homogenous or 
speckled. ANA is often present many years before the clinical manifestation of 
an autoimmune disease. As we have found ANA in remarkably younger age in 
AD patients, we could suggest higher risk for autoimmune diseases in patients 
with AD, especially those with AD since early infancy. Therefore patients with 
active and severe AD should be considered for screening for ANA, and ANA-
positive (especially in high titer) patients should be regularly followed-up, as 
these patients could be disposed to earlier development of systemic 
autoreactivity. 
 
6.3.2. IgA type antibodies to transglutaminase 1 and 3 and  
their potential role in pathogenesis of AD 
In recent years, characterisation of skin-related immune processes and 
involvement of autoimmune reactions associated with the pathogenesis of AD 
have received much attention (Liedén et al 2012; Tang et al 2012). So far, there 
is no reliable biomarker or autoantigen that can distinguish AD from other 
diseases (Eichenfield et al 2014). As skin barrier defects play an important role 
in pathogenesis of AD, and epidermal transglutaminases have been suggested as 
playing a role in skin barrier repair (Cheng et al 2009; de Koning et al 2012; 
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Liedén et al 2012), we hypothesised that IgA-anti-TG1 and IgA-anti-TG3 could 
play a role in AD development.  
We found significantly higher levels of IgA-anti-TG1 and IgA-anti-TG3 in 
CD patients, but not in patients with AD, suggesting that circulating IgA 
antibodies specific for TG isoenzymes expressed in the dermis are not 
characteristic of AD. 
In accordance with earlier studies (Marietta et al 2008; Jaskowski et al 
2009), we found IgA-anti-TG3 in 18% of CD patients. Considering IgA-anti-
TG3 as a marker for DH, the finding may indicate the clinical development of 
the CD skin phenotype later in life (Hull et al 2008). However, the high pre-
valence (36%) of IgA-anti-TG1 responses in CD patients has not been reported 
before and is therefore difficult to explain.  
We found moderate correlation between IgA-anti-TG2 and IgA-anti-TG1 or 
IgA-anti-TG3, indicating possible cross-reactivity between tested TGs. 
Nevertheless, we claim that antigen-specific IgA reactions exist against separate 
TGs, as none of the controls or AD patients had significantly elevated IgA-anti-
TG1 and/or IgA-anti-TG3 in association with IgA-anti-TG2. 
Based on our results, circulating antibodies to TG1 and TG3 might not be 
related to AD. Whether these antibodies have a role in AD pathogenesis will 
require further studies focusing on IgA-anti-TG1 and IgA-anti-TG3 






1. Our nationwide study including all diagnosed children with CD up to 19 
years of age showed more than a 30-fold increase in the incidence of CD 
together with a shift towards older age and atypical presentation over a 35-
year period. However, prevalence of childhood CD in Estonia is at least 
0.34% in a random sample of schoolchildren aged 9 and 15 years and it has 
not changed during the 10 years of follow-up.  
2. Prevalence of CD in children with AD is more than four times higher than 
in the general children population in Estonia. In AD patients, CD tends to 
manifest with atypical gastrointestinal symptoms or asymptomatically, 
therefore, children with active AD should be considered for screening for 
CD in order to prevent serious long-term complications due to small 
intestinal mucosal damage. Special attention should be paid to AD patients 
with gastrointestinal symptoms. 
3. The frequency of ANA positivity does not differ between children with AD 
and the control group. No difference in ANA-positivity was found between 
intrinsic and extrinsic subtypes of AD or between different sensitisation 
patterns. In AD patients, ANA was found in younger patients and in slightly 
higher titres, but the difference was not significant compared to controls.  
4. IgA-anti-TG1 and IgA-anti-TG3 were more common and in higher levels 
among patients with CD when compared to controls or AD patients. In CD 
patients, the antibodies tended to appear simultaneously, but not in AD 
patients. The higher prevalence of IgA-anti-TG3 in CD patients may 
indicate the development of skin phenotype of CD in later life. The level of 
circulating antibodies might not be related with the skin lesions and the 
future work should focus on measuring IgA-anti-TG1 and IgA-anti-TG3 in 




8. FUTURE PROSPECTS 
The present study shows more than a 30-fold increase in the incidence of CD 
together with a shift towards atypical clinical presentation and older age of 
presentation during a 35-year period in Estonia. As recent publications have 
reported increasing prevalence of CD in older age groups, it would be 
interesting to follow-up with the random schoolchildren population to find out 
the rate of new CD cases in adulthood. Also, the recent works put the focus 
back on the microbial load and the potential protective measures (infant feeding 
practices, use of pre- and probiotics, etc) that would provide us with valuable 
information for preventing CD in high-risk populations. 
The more than four times higher prevalence of CD in AD patients compared 
to the general population emphasizes the need of larger international 
multicentered study for evaluating the (cost)effectiveness of screening AD 
patients for CD (as a risk group), as it has been applied for type 1 diabetes.  
Autoimmune reactions in AD pathogenesis should deserve more attention in 
future studies, concentrating on finding autoantigen target for AD and specific 
biomarkers for differentiating phenotypes of AD. As our results indicate that 
circulating antibodies to TG1 and TG3 might not be related to AD, future 
studies should focus on assessing the role of IgA-anti-TG1 and IgA-anti-TG3 in 
AD pathogenesis at the skin level. Based on the associations found between AD 
and CD – two chronic inflammatory diseases with dysregulated immune 
responses, the role of FOXP3+CD25+ Treg and dendritic cell subgroups in 






SUMMARY IN ESTONIAN 
Lapseea tsöliaakia Eestis, esinemine atoopilise dermatiidiga  
lastel ja koosesinemise immunoloogiline iseloomustus 
Tsöliaakia on multifaktoriaalne krooniline haigus, mille korral nisu-, rukki-, 
odra- ja võimalik, et ka kaeravalkude poolt vallandatavad ning koe- ehk 2. tüüpi 
transglutaminaasi vastu tekkivad autoimmuunreaktsioonid põhjustavad päriliku 
eelsoodumusega isikutel peensoole limaskesta kahjustuse – hattude atroofia ja 
krüptide hüpertroofia. Tsöliaakia tekkes on oluline roll nii geneetilisel eel-
soodumusel (ligikaudu 95%-l haigetest on leitud HLA DR3DQ2 haplotüüp) kui 
ka loomulikul ja omandatud immuunvastusel. Patofüsioloogiliste protsesside 
kaskaad saab tõenäoliselt alguse peensoole limaskesta barjäärifunktsiooni 
häirumisest, sellele järgneb toksiliste peptiidide esitlemine antigeeni esitlevate 
rakkude pinnal olevate HLA DQ2 või DQ8 molekulide kaudu T-helper 
lümfotsüütidele, mille tulemusena vabanevad mitmed proinflammatoorsed 
tsütokiinid. Järgneb autoreaktiivsete B-rakkude proliferatsioon ning plasma-
rakkude poolt deamideeritud gliadiinipeptiidide-, endomüüsiumi- ja koetrans-
glutaminaasivastaste antikehade produktsioon. Põletikulise reaktsiooni tõttu 
suureneb intraepiteliaalsete lümfotsüütide hulk peensoole limaskestas ning 
tsütotoksiliste mediaatorite vabanemine viib enterotsüütide kahjustuse ja 
hattude atroofia tekkeni. Põletikust tingitud kahjustus kutsub aga esile koe-
transglutaminaasi vabanemise, suurendades seeläbi ka T-lümfotsüütide reak-
tiivsust.  
Tsöliaakia varajane avastamine ja seega õigeaegne ravi on iseäranis oluline, 
sest see võimaldab vältida ulatuslikust peensoolelimaskesta kahjustusest tule-
nevaid tüsistusi – kasvupeetust, jäävhammaste struktuuri defekte, rauavaegus-
aneemiat, osteoporoosi, reproduktiivse funktsiooni häireid, pahaloomulisi 
kasvajaid. Tsöliaakia ainus ravi on range ja eluaegne gluteenivaba dieet, mille 
toimel peensoole limaskest paraneb ning vaevused ja sümptomid taanduvad. 
Uutele rahvusvahelistele tsöliaakia diagnostika ja ravijuhistele tuginedes on 
klassikalise tsöliaakia korral peamiseks ilminguks malabsorptsioonisündroom 
(korduv või krooniline kõhulahtisus koos kaalu- ja kasvupeetuse või kõhnu-
misega), seevastu atüüpiliste seedetrakti vaevuste korral kaalu- ja kasvupeetust 
ega kõhnumist ei kaasu. Lisaks võib tsöliaakia väljenduda seedetraktiväliste 
vaevustega või hoopis asümptomaatilisena.  
Kuni 1990 aastateni peeti tsöliaakiat harvaesinevaks lastehaiguseks, sest 
peamiselt kliinilisele kahtlusele tuginenud diagnoosimise alusel leiti erinevates 
riikides haigust vähem kui 0,1%-l lastest. Kuid viimastel aastatel läbiviidud 
uuringutele (sh sõeluuringutele) tuginedes esineb tsöliaakiat palju sagedamini 
kui senini on arvatud ja avastatud, kuni 3% rahvastikust, ning üha sagedamini 
ka vanemas eas. Seejuures on ligikaudu pooled haigusjuhud varjatud või atüüpi-
lise kliinilise pildiga, jäädes seetõttu sageli õigeaegselt diagnoosimata.  
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Ka Eestis on tsöliaakiat peetud kaua väga harva esinevaks haiguseks – 
aastatel 1976–1989 diagnoositi Eestis vaid 0,04 juhtu 1000 elusalt sündinu 
kohta. Ajavahemikul 1990–1994 läbiviidud aktiivse kliinilise otsingu ja kogu 
Eestis rakendatud sõeluuringute abil sagenes tsöliaakia diagnoosimine küll 
oluliselt (0,37 uut juhtu 1000 elusalt sündinu kohta), kuid võrreldes teiste 
riikidega jäi erinevus siiski umbes kümnekordseks. 
Tsöliaakiat on kirjeldatud koos ligi 100 erineva haigusega, kõige sagedamini 
koos I tüüpi suhkurtõve, erinevate autoimmuunhaiguste või kromosomaalsete 
häiretega. Kaasuva haiguse foonil avaldub tsöliaakia sageli varjatud või atüüpi-
lises vormis ning seetõttu jääb sageli õigeaegselt avastamata. Atoopilise derma-
tiidi ja tsöliaakia, kui kahe lapseea kõige sagedamini esineva kroonilise 
immuunsüsteemi haiguse omavaheline seos on senini täpselt teadmata. 
Atoopiline dermatiit on multifaktoriaalne krooniline põletikuline nahahaigus, 
mida iseloomustab naha sügelus, eksematoosne lööve näo piirkonnas, käte ja 
jalgade sirutus- (imikutel ning väikelastel) ning painutuspindadel (vanematel 
lastel). Kirjanduse andmetel esineb atoopiline dermatiit 10–20% lastest. Atoopi-
lise dermatiidi tekkes on oluline roll nii geneetilisel eelsoodumusel, väliskesk-
konna faktoritel, naha barjäärifunktsiooni häirumisel kui ka immunoregulatoor-
setel mehhanismidel. Haigust võib klassifitseerida väliste ja sisemiste faktorite 
poolt vahendatud alavormidesse. Varasemalt peeti atoopilist dermatiiti puhtalt 
T-helper 2 raku poolt vahendatud haiguseks, kuid viimaste aastate uuringutega 
on selgunud, et ka autoimmuunreaktsioonid etendavad antud haiguse pato-
geneesis olulist rolli. Kuigi valdaval osas atoopilise dermatiidi patsientidest ei 
esine kõrgenenud üldist IgE taset ega allergeenide suhtes sensibiliseerumist, on 
lastel sageli leitud sensibiliseerumist toiduallergeenide suhtes, kuid nähtuse 
põhjuslikkuse osas ei ole jõutud ühisele seisukohale. Kuna toiduallergia korral 
on leitud, et haigete peensoolelimaskesta permeaabelsus on märkimisväärselt 
suurenenud, siis võib seedetrakti limaskesta permeaabelsuse muutustel ning 
limaskesta kahjustusel olla teatav roll ka atoopilise dermatiidi tekkes. 
Üksikud varasemad uuringud viitavad, et tsöliaakia ja allergilised haigused 
võivad esineda samaaegselt. Kirjanduse andmetel esineb tsöliaakiahaigetel 
allergiat sagedamini kui üldpopulatsioonis. Samuti on leitud, et tsöliaakia-
haigetel on atoopia 1. tüüpi diabeedi järel tsöliaakiaga kõige sagedamini kaasuv 
haigus ning tsöliaakiahaigetel on atoopilise dermatiidi tekkeks võrreldes 
üldpopulatsiooniga kolmekordne risk. Samas on ka atoopilise dermatiidi pat-
sientide hulgas sagedamini leitud autoimmuunnähte ning ka tsöliaakiat. Senini 
on erialakirjanduses diskuteeritav, kas tsöliaakia ja atoopilise dermatiidi koos-
esinemine on juhuslik või on tegemist tõelise assotsiatsiooni ja ühiste pato-
geneetiliste mehhanismidega. Kuigi nii tsöliaakia kui atoopilise dermatiidi 
patogneesis osalevad sarnased immunoloogilised komponendid, ei ole teada kas 
need mõjutavad ka nende haiguste koosesinemist. 
Käesoleva uuringu eesmärgiks oli: 
‒ hinnata tsöliaakia haigestumust Eesti lastel ja iseloomustada haigestumuses 
ja kliinilises avaldumises esinevaid muutusi, 
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‒ hinnata tsöliaakia levimust aktiivse atoopilise dermatiidiga lastel ja ise-
loomustada atoopilise dermatiidi ja tsöliaakia koosesinemise kliinilisi 
eripärasid, 
‒ hinnata atoopilise dermatiidiga laste üldist autoimmuunset tausta ja ise-
loomustada patsientide erinevusi tulenevalt tuumavastaste antikehade 
olemasolust, 
‒ määrata IgA tüüpi autoantikehad epidermaalsete transglutaminaaside (trans-
glutaminaas 1 ja 3) vastu vereseerumis ning hinnata nende antikehade 
potentsiaalset rolli atoopilise dermatiidi patogeneesis. 
 
Tsöliaakia levimuse hindamiseks viidi läbi tsöliaakia sõeluuringud juhusliku 
valimi alusel 1998–1999 aastal kogutud 1160 Tartumaa 9 ja 15 aastasel kooli-
lapsel. Sama gruppi uuriti korduvalt 10-aastase perioodi möödudes 2007–2008 
aastal.  
Tsöliaakia haigestumuse hindamiseks Eestis analüüsiti perioodil 1976–2010 
kõiki Eesti lastel diagnoositud tsöliaakia esmasjuhte. Andmed on kogutud Tartu 
Ülikooli Kliinikumi Lastekliinikust ja Tallinna Lastehaiglast.  
Lisaks kaasati uuringusse 351 järjestikust aktiivse atoopilise dermatiidiga 
last Tallinna Lastehaiglast ning 28 histoloogiliselt kinnitatud tsöliaakiaga last 
Tallinna Lastehaiglast ja Tartu Ülikooli Kliinikumi Lastekliinikust. Kontroll-
grupi moodustasid muudel põhjustel hospitaliseeritud 56 last Tallinna Laste-
haiglast, kellel muudel põhjustel teostatud gastroskoopia abil on kinnitatud 
histoloogiliselt normaalne peensoole limaskest, ning 61 last Tartu Ülikooli 
Kliinikumi Lastekliinikust. Kontrollgruppi kaasatud lastel eelnevalt teostatud 
uuringute tulemusena autoimmuunset ega ägedat põletikulist haigust ei leitud. 
Koolilastel läbiviidud uuringute alusel leidsime tsöliaakia levimuseks Eesti 
lastel vähemalt 0,34%. Sama grupi korduval uurimisel kümne aastase perioodi 
järel uusi tsöliaakiajuhte ei lisandunud. Samas hinnates tsöliaakia haigestumust 
kogu Eestis diagnoositud lastel, selgub enam kui 30-kordne haigestumuskordaja 
tõus 35-aastase uuringuperioodi jooksul – aastatel 1976–1980 diagnoositi vaid 
0,10 juhtu 100 000 inimaasta kohta, seevastu aastatel 2006–2010 diagnoositi 
3,14 juhtu 100 000 inimaasta kohta. Samas on aastate lõikes täheldatav nii 
märkimisväärne keskmise vanuse tõus diagnoosimisel kui ka haiguse kliinilise 
pildi varieeruvus – kui uuringu algaastatel diagnoositi kõik tsöliaakiajuhud alla 
kaheaastastel tüüpiliste seedetrakti kaebustega lastel, siis uuringu viimastel 
aastatel diagnoositi enamus juhte atüüpilise või asümptomaatilise väljendusega 
lastel, kellel vanust üle viie aasta.  
Atoopilise dermatiidiga laste grupis diagnoositi tsöliaakia viiel lapsel 351-st 
(1,4%). Viiest diagnoositud lapsest kolmel esinesid väljendunud seedetrakti 
vaevused ning peensoole histoloogilisel uuringul leiti vähemalt osaline hattude 
atroofia (Marsh IIIa–IIIc). Ülejäänud kahel diagnoositud lapsel tsöliaakiale 
viitavaid kaebusi ei esinenud, kuigi vereanalüüsis leiti kõrges tiitris IgA tüüpi 
koetransglutaminaasivastased antikehad ning peensoole histoloogilisel uuringul 
esines väljendunud hattude atroofia (Marsh IIIb ja IIIc).  
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Kui võrrelda tsöliaakia levimust koolilastel ja atoopilise dermatiidiga lastel, 
siis on risk tsöliaakia tekkeks atoopilise dermatiidiga laste hulgas üle nelja korra 
kõrgem. Tulenevalt tsöliaakia sagedasest atüüpilisest või asümptomaatilisest 
avaldumisest ning atoopilise dermatiidiga patsientide suurenenud riskist, oleks 
soovitatav kaaluda atoopilise dermatiidiga patsientidel plaaniliste tsöliaakia 
sõeluuringute teostamist, vältimaks peensoole kahjustusest tingitud tüsistusi. 
Kindlasti soovitame võimaliku tsöliaakia suhtes uurida atoopilise dermatiidi 
patsiente, kellel esinevad seedetrakti vaevused. 
Valdaval osal uuritud atoopilise dermatiidi patsientidest (70,2%) esines 
väliste faktorite poolt vahendatud atoopilise dermatiidi vorm ning enamikul oli 
täheldatava kõrgenenud üldine IgE tase (59,5%) ja sensibiliseerumine toidu-
allergeenide suhtes (44,2%). Mitmed uuringud on atoopilise dermatiidi tekkes ja 
progressioonis täheldanud teatavat rolli autoimmuunreaktsioonidel, kuigi 
haigusspetsiifilist autoantigeeni ega biomarkerit seni leitud ei ole. Teostatud 
uuringutega leidsime tuumavastaseid antikehi võrdselt nii kontrollgrupi patsien-
tidel kui ka atoopilise dermatiidiga patsientidel. Kuigi need antikehad esinesid 
atoopilise dermatiidiga patsientidel veidi kõrgemas tiitris ja nooremas vanuses 
võrreldes kontrollgrupiga, ei olnud erinevused statistiliselt olulised. Tuuma-
vastaseid antikehi leiti sagedamini kõrgenenud IgE tasemega patsientidel 
(15,0% vs 1,4) ja väliste faktorite poolt vahendatud atoopilise dermatiidiga 
vormiga patsientidel (15,2% vs 9,7%), kuid erinevused ei olnud statistiliselt 
olulised.  
Kuna autoantikehad ilmuvad sageli aastaid enne autoimmuunhaiguse välja-
kujunemist, siis võivad saadud tulemused viidata suurenenud autoimmuun-
reaktsioonide riskile varajase algusega aktiivse atoopilise dermatiidi korral. 
Seetõttu peaks atoopilise dermatiidiga patsiente uurima tuumavastaste anti-
kehade suhtes ning jälgima võimaliku autoimmuunhaiguse väljakujunemise 
osas. 
Atoopilise dermatiidi patogeneesis on viimase aja uuringute põhjal oluline 
roll naha kaitsebarjääri häirumisel ja selle taastamisel. Tulenevalt epider-
maalsete transglutaminaaside võimalikust rollist epidermaalse barjääri taasta-
mises, võiks neil olla ka teatav roll atoopilise dermatiidi patogeneesis. Uurides 
aga atoopilise dermatiidi, tsöliaakia ja kontrollgrupi lapsi transglutaminaas 1 ja 
3 vastaste antikehade suhtes, leidsime antud antikehi tsöliaakiapatsientidel 
oluliselt suuremas hulgas kui atoopilise dermatiidi või kontrollgrupi 
patsientidel. Seega ei ole alust tsirkuleerivaid epidermaalsete transglutami-
naaside vastaseid antikehi seostada atoopilise dermatiidi korral esineva naha-
kahjustusega. Nende võimaliku rolli väljaselgitamiseks atoopilise dermatiidi 
patogeneesis oleks vajalik hinnata antud antikehi atoopilise dermatiidiga 
patsientide nahabiopsias. 
Lähtudes antud uurimuse tulemustest võib väita, et tsöliaakia esineb Eestis 
oluliselt sagedamini kui varasemalt arvatud (vähemalt 0,34%) ning väljendub 
üha sagedamini atüüpiliste kaebustega või hoopis asümptomaatiliselt ning 
enamasti (71,7%) üle viie aasta vanustel lastel. 
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Atoopilise dermatiidiga patsientide hulgas esineb tsöliaakiat üle nelja korra 
sagedamini kui üldrahvastikus (1,4% vs 0,34%), mistõttu vältimaks peensoole 
limaskesta kahjustusest tulenevaid tüsistusi, tuleks kaaluda atoopilise dermatiidi 
lisamist tsöliaakia riskigruppide hulka (nagu seda on tehtud 1. tüüpi dia-
beediga).  
Atoopilise dermatiidi korral võivad tuumavastased autoantikehad esineda 
juba varases eas ning seetõttu tuleks eeskätt raskekululise atoopilise derma-
tiidiga patsiente uurida nende antikehade suhtes ning antikeha-positiivseid 
patsiente jälgida regulaarselt võimaliku autoimmuunhaiguse väljakujunemise 
suhtes. 
Tsirkuleerivad epidermaalsete transglutaminaaside (transglutaminaas 1 ja 3) 
vastased antikehad ei assotsieeru atoopilise dermatiidi puhuse nahakahjus-
tusega. Samas on transglutaminaas 1 ja 3 vastased antikehad sageli leitavad 
tsöliaakiaga patsientidel (vastavalt 36% ja 18%), samaaegselt koetransglutami-
naasi vastaste antikehadega. Transglutaminaas 3 vastaste antikehade leid võib 
viidata herpetiformse dermatiidi kõrgenenud tekke riskile, kuid transgluta-
minaas 1 vastaste antikehade esinemine vajab edasisi täpsustavaid uuringuid. 
Transglutaminaaside võimaliku rolli hindamiseks atoopilise dermatiidi pato-
geneesis oleks vajalikud edasised täpsustavad uuringud atoopilise dermatiidi 
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